Navigation Links
New Institute Paves Way for Rapid Cancer Drug Development
Date:10/12/2010

GREENVILLE, S.C., Oct. 12 /PRNewswire-USNewswire/ -- Greenville Hospital System University Medical Center (GHS) unveiled details of its new Institute for Translational Oncology Research, a visionary cancer initiative that will help pave the way for new breakthroughs in rapid drug development, diagnostic discovery and advanced cancer care. ITOR is part of the GHS Cancer Center, a recognized regional multi-disciplinary center.

ITOR partners will include leading pharmaceutical companies, research universities, private industry and the government. GHS made the announcement today (Oct. 12).

The new institute, known as ITOR, builds on the success of GHS' Clinical Research Unit and its rapidly-developing biorepository tissue-banking service, which helped make GHS one of the country's prominent players in the development of promising new oncology drugs. Numerous first-in-human studies have been conducted through the CRU, which began in 2004 as part of GHS' long-standing relationship with Cancer Centers of the Carolinas.  

The evolving institute is steadily moving into the arena of personalized gene-based cancer therapies, which match the treatment to tumor-specific genetic abnormalities and patient-specific predictors of toxicity. Such translational research helps bring discovery directly from the lab to practical applications in patients. Part of ITOR's strength is its focus on using innovative public and private sector partnerships and initiatives to advance leading-edge cancer care.

"Through ITOR, we will be able to make new therapies accessible to patients far more quickly than traditional models have allowed," said Joe Stephenson, M.D., who serves as the institute's medical director.

To accomplish the goal of speeding-up the delivery of patient-specific therapies, ITOR strives to identify new ways to achieve earlier prediction of drug success, find new applications and patients for existing drugs and integrate advanced molecular and gene-based technologies into diagnostic and treatment protocols.

In practical terms, that means ITOR is focused on developing a more personalized approach to cancer therapy – targeting the right drug to the right patient – by integrating leading-edge technologies such as molecular profiling into an enhanced drug validation process.

Pharmaceutical and industry partners include long-time collaborator U.S. Oncology, Caris Life Sciences and Lab21, as well as Amgen, AstraZeneca, Japanese-based Eisai Pharmaceuticals, Oncolix and Novartis, which recently selected ITOR as one of its newest designated phase 1 clinical trial sites. Early academic partners also include the Cancer Research Center of the University of South Carolina.

For a complete list of partners and more information on ITOR, go to ITOR-ghs.org.


'/>"/>
SOURCE Greenville Hospital System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ECRI Institute Names Kaiser Permanente Winner of 5th Annual Health Devices Achievement Award
2. ACD Wins $3 Million Grant From National Cancer Institute to Develop Its CTCscope™ System for Detection and Molecular Analysis of Circulating Tumor Cells
3. Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
4. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
5. West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0
6. Roskamp Institute to Begin Human Alzheimers Clinical Trials With a Natural Compound in Tobacco
7. American College of Surgeons Health Policy Research Institute Releases Surgery Workforce Atlas That Shows Surgeon Shortage Across the U.S.
8. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
9. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
10. National Pharmaceutical Council Comments on Patient-Centered Outcomes Research Institute Board of Governors
11. Wolters Kluwer Health and the Joanna Briggs Institute Enter Exclusive Relationship to Deliver Evidence-Based Clinical Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Report analyzes the worldwide markets for Endodontic Supplies in US$ ... Canada , Japan , ... Latin America , and Rest of World. ... through 2022. Also, a six-year historic analysis is provided for ... and secondary research. Company profiles are primarily based on public ...
(Date:2/24/2017)... -- ITL Limited, ( ASX : ITD ), une société ... les excellents résultats semestriels clos le 31 décembre 2016 ... complète « Résultats et mise à jour sur la croissance ... Faits marquants ... en hausse de 104 %) Bénéfice par ...
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
Breaking Medicine Technology:
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that it will soon begin franchising throughout the U.S. starting this spring. Current ... bring the practice of meditation mainstream. Current Meditation will be the first meditation ...
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first ... will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA ... CEO of the Virginia Mason Health System in Seattle since 2000. In addition to ...
Breaking Medicine News(10 mins):